Cost-effectiveness analysis of plasma versus recombinant factor viia for placing intracranial pressure monitors in pretransplant patients with acute liver failure

Clinical and Applied Thrombosis/Hemostasis

Volumn 20, Issue 6, 2014, Pages 607-614

  Pham, Huy P ^a,b   Sireci, Anthony N ^a   Kim, Chong H ^c   Schwartz, Joseph ^a  

^a Department of Medicine   (United States)

^b University of Alabama at Birmingham   (United States)

^c Department of Medicine   (United States)

Author keywords

Acute liver failure; Cost effective; Intracranial pressure monitor; Novoseven; Plasma transfusion; Recombinant activated factor VII

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 7A; RECOMBINANT FVIIA; RECOMBINANT PROTEIN;

ACUTE LIVER FAILURE; ALGORITHM; ARTICLE; BLOOD CLOTTING DISORDER; BLOOD TRANSFUSION REACTION; COST EFFECTIVENESS ANALYSIS; DECISION TREE; GRAFT RECIPIENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; INTRACRANIAL PRESSURE MONITOR; INTRACRANIAL PRESSURE MONITORING; PLASMA TRANSFUSION; PRIORITY JOURNAL; THEORETICAL MODEL; THROMBOSIS; BLOOD COMPONENT THERAPY; COST; ECONOMICS; FEMALE; LIVER FAILURE, ACUTE; LIVER TRANSPLANTATION; MALE; PLASMA; STATISTICAL MODEL;

ALGORITHMS; BLOOD COMPONENT TRANSFUSION; COSTS AND COST ANALYSIS; FACTOR VIIA; FEMALE; HUMANS; LIVER FAILURE, ACUTE; LIVER TRANSPLANTATION; MALE; MODELS, ECONOMIC; PLASMA; RECOMBINANT PROTEINS;

EID: 84906064066     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029614524621     Document Type: Article

References (31)

1. Sass DA, Shakil AO. Fulminant hepatic failure. Liver Transpl. 2005;11(6):594-605.
2. Atillasoy E, Berk PD. Fulminant hepatic failure: pathophysiology, treatment, and survival. Annu Rev Med. 1995;46:181-191.
3. Zafirova Z, O'Connor M. Hepatic encephalopathy: current management strategies and treatment, including management and monitoring of cerebral edema and intracranial hypertension in fulminant hepatic failure. Curr Opin Anaesthesiol. 2010;23(2): 121-127.
4. Bernal W, Wendon J. Acute liver failure. N Engl J Med. 2013; 369(26):2525-2534.
5. Vaquero J. Therapeutic hypothermia in the management of acute liver failure. Neurochem Int. 2012;60(7):723-735.
6. Desjardins P, Du T, Jiang W, Peng L, Butterworth RF. Pathogenesis of hepatic encephalopathy and brain edema in acute liver failure: role of glutamine redefined. Neurochem Int. 2012;60(7): 690-696.
7. Vaquero J, Fontana RJ, Larson AM, et al. Complications and use of intracranial pressure monitoring in patients with acute liver failure and severe encephalopathy. Liver Transpl. 2005;11(12): 1581-1589.
8. Stravitz RT, Kramer AH, Davern T, et al. Intensive care of patients with acute liver failure: recommendations of the U.S. Acute liver failure study group. Crit Care Med. 2007;35(11): 2498-2508.
9. Pereira SP, Langley PG, Williams R. The management of abnormalities of hemostasis in acute liver failure. Semin Liver Dis. 1996;16(4):403-414.
10. Munoz SJ, Stravitz RT, Gabriel DA. Coagulopathy of acute liver failure. Clin Liver Dis. 2009;13(1):95-107.
11. Shami VM, Caldwell SH, Hespenheide EE, Arseneau KO, Bickston SJ, Macik BG. Recombinant activated factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapy. Liver Transpl. 2003;9(2):138-143.
12. Davis JW, Davis IC, Bennink LD, et al. Placement of intracranial pressure monitors: are ''normal'' coagulation parameters necessary? J Trauma. 2004;57(6):1173-1177.
13. Spector I, Corn M, Ticktin HE. Effect of plasma transfusions on the prothrombin time and clotting factors in liver disease. N Engl J Med. 1966;275(19):1032-1037.
14. Youssef WI, Salazar F, Dasarathy S, Beddow T, Mullen KD. Role of fresh frozen plasma infusion in correction of coagulopathy of chronic liver disease: a dual phase study. Am J Gastroenterol. 2003;98(6):1391-1394.
15. Yang L, Stanworth S, Hopewell S, Doree C, Murphy M. Is freshfrozen plasma clinically effective? an update of a systematic review of randomized controlled trials. Transfusion. 2012;52(8): 1673-1686.
16. Logan AC, Goodnough LT. Recombinant factor VIIa: an assessment of evidence regarding its efficacy and safety in the off-label setting. Hematology Am Soc Hematol Educ Program. 2010;2010: 153-159.
17. Le TV, RumbakMJ, Liu SS, Alsina AE, van Loveren H, Agazzi S. Insertion of intracranial pressure monitors in fulminant hepatic failure patients: early experience using recombinant factor VII. Neurosurgery. 2010;66(3):455-458.
18. Popovsky MA, Moore SB. Diagnostic and pathogenetic considerations in transfusion-related acute lung injury. Transfusion. 1985;25(6):573-577.
19. Levi M, Levy JH, Andersen HF, Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med. 2010;363(19):1791-1800.
20. Center for Medicaid and Medicare Services. 2009 Physician Fee Schedule. In: Center for Medicaid and Medicare Services. Baltimore: Centers for Medicare & Medicaid Services; 2009.
21. Healthcare Cost and Utilization Project. Agency for Healthcare Research and Quality, 2009. http://hcupnet.ahrq.gov/. Accessed January 13, 2013.
22. Mazzei C, Popovsky M, Kopko P. Noninfectious complications of blood transfusion. In: Roback J, Combs M, Grossman B, & Hillyer C, eds. Technical Manual (16th ed). Baltimore: AABB; 2008:715-749.
23. Rana R, Fernandez-Perez ER, Khan SA, et al. Transfusion-related acute lung injury and pulmonary edema in critically ill patients: a retrospective study. Transfusion. 2006;46(9):1478-1483.
24. Popovsky MA, Audet AM, Andrzejewski C Jr. Transfusionassociated circulatory overload in orthopedic surgery patients: a multi-institutional study. Immunohematology. 1996;12(2):87-89.
25. Bierbaum BE, Callaghan JJ, Galante JO, Rubash HE, Tooms RE, Welch RB. An analysis of blood management in patients having a total hip or knee arthroplasty. J Bone Joint Surg Am. 1999;81(1): 2-10.
26. Narick C, Triulzi DJ, Yazer MH. Transfusion-associated circulatory overload after plasma transfusion. Transfusion. 2012;52(1): 160-165.
27. Li G, Rachmale S, Kojicic M, et al. Incidence and transfusion risk factors for transfusion-associated circulatory overload among medical intensive care unit patients. Transfusion. 2011;51(2): 338-343.
28. Toy P, Gajic O, Bacchetti P, et al. Transfusion-related acute lung injury: incidence and risk factors. Blood. 2012;119(7): 1757-1767.
29. Logan AC, Yank V, Stafford RS. Off-label use of recombinant factor VIIa in U.S. hospitals: analysis of hospital records. Ann Intern Med. 2011;154(8):516-522.
30. Pham HP, Hsu SX, Parker-Jones S, Samstein B, Diuguid D, Schwartz J. Recombinant activated factor VII in patients with acute liver failure with UNOS Status 1A: a single tertiary academic centre experience. Vox Sang. 2014;106(1):75-82.
31. Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med. 2011;365(2):147-156.